The application of Oncotype DX 21-gene assay in early-stage ER positive breast cancer / 中国癌症杂志
China Oncology
;
(12): 675-680, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-613086
ABSTRACT
Several multi-gene assays have been developed to predict the risk of recurrence in patients with early-stage, estrogen receptor (ER) positive breast cancer. Among them, Oncotype DX 21-gene assay is widely applied among node-negative patients because of its unique prediction of therapeutic benefit. Although many retrospective stud-ies have proved its prognostic and predictive value in node-positive population, evidence from large prospective clinical trials remains insufficient. When combined with clinicopathological variables, the assay has been shown to impact adjuvant treatment decision making in a cost-effective manner. This article reviewed the available clinical evidence for the prognostic and predictive value, unique advantages, the effect on treatment decision making, cost-effectiveness and contradictories of 21-gene assay in early-stage luminal breast cancer patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Observational study
/
Prognostic study
Language:
Chinese
Journal:
China Oncology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS